JP2018534244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534244A5 JP2018534244A5 JP2018512554A JP2018512554A JP2018534244A5 JP 2018534244 A5 JP2018534244 A5 JP 2018534244A5 JP 2018512554 A JP2018512554 A JP 2018512554A JP 2018512554 A JP2018512554 A JP 2018512554A JP 2018534244 A5 JP2018534244 A5 JP 2018534244A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- brain
- polymer
- formulation
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 53
- 210000004556 brain Anatomy 0.000 claims description 17
- 229920000642 polymer Polymers 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 13
- 239000002105 nanoparticle Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 238000009792 diffusion process Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000001261 hydroxy acids Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000000819 hypertonic solution Substances 0.000 claims description 2
- 229940021223 hypertonic solution Drugs 0.000 claims description 2
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- -1 polyethylene Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 230000003204 osmotic effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217194P | 2015-09-11 | 2015-09-11 | |
| US62/217,194 | 2015-09-11 | ||
| PCT/US2016/050967 WO2017044759A1 (en) | 2015-09-11 | 2016-09-09 | Compositions and methods to improve nanoparticle distribution within the brain interstitium |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534244A JP2018534244A (ja) | 2018-11-22 |
| JP2018534244A5 true JP2018534244A5 (enExample) | 2019-10-24 |
| JP6824535B2 JP6824535B2 (ja) | 2021-02-03 |
Family
ID=56959073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512554A Active JP6824535B2 (ja) | 2015-09-11 | 2016-09-09 | 脳間質内のナノ粒子分布を改善するための組成物および方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US10632080B2 (enExample) |
| JP (1) | JP6824535B2 (enExample) |
| WO (1) | WO2017044759A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2020072357A1 (en) * | 2018-10-04 | 2020-04-09 | University Of Rochester | Improvement of glymphatic delivery by manipulating plasma osmolarity |
| WO2020210805A1 (en) * | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008091465A2 (en) * | 2006-12-21 | 2008-07-31 | Wayne State University | Peg and targeting ligands on nanoparticle surface |
| CN101657189B (zh) * | 2007-02-13 | 2014-11-26 | 康奈尔大学 | 对流增强型递送装置，方法和应用 |
| CA2702180A1 (en) * | 2007-10-12 | 2009-04-16 | Peter Humphries | Method for opening tight junctions |
| WO2012039979A2 (en) * | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| KR101811917B1 (ko) * | 2012-01-19 | 2017-12-22 | 더 존스 홉킨스 유니버시티 | 점액 침투 강화를 나타내는 나노 입자 제형 |
| US9937270B2 (en) * | 2014-05-12 | 2018-04-10 | The John Hopkins University | Engineering synthethic brain penetrating gene vectors |
-
2016
- 2016-09-09 WO PCT/US2016/050967 patent/WO2017044759A1/en not_active Ceased
- 2016-09-09 JP JP2018512554A patent/JP6824535B2/ja active Active
- 2016-09-09 US US15/759,465 patent/US10632080B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018162284A5 (ja) | 複数の被覆された粒子を含む組成物及び医薬製剤 | |
| US20240245646A1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| AU2013209452B2 (en) | Nanoparticle formulations with enhanced mucosal penetration | |
| JP2010502713A5 (enExample) | ||
| JP2015519330A5 (enExample) | ||
| JP2015523355A5 (enExample) | ||
| WO2012160088A1 (de) | Biokompatible nano- und mikropartikel beschichtet mit stabilisatoren für die pulmonale applikation | |
| JP2018534244A5 (enExample) | ||
| Manna et al. | Marine polysaccharides in tailor-made drug delivery | |
| US10300017B2 (en) | Method and composition for treating cystitis | |
| Pan et al. | Luteolin‐Loaded Hyaluronidase Nanoparticles with Deep Tissue Penetration Capability for Idiopathic Pulmonary Fibrosis Treatment | |
| Abdalla et al. | Poloxamer micellar system for intra-articular injection of 15-deoxy-Δ12, 14-prostaglandin J2 with improved bioavailability and anti-inflammatory properties in the temporomandibular joint of rats | |
| JP2017515839A5 (enExample) | ||
| JP2018535952A5 (enExample) | ||
| JP2022534278A (ja) | 血液脳関門（ｂｂｂ）の保護及び修復のための組成物 | |
| Sun et al. | Bergenin and vitexin delivery platform using mouse lung fibroblasts-derived exosomes for bleomycin-induced pulmonary fibrosis therapy | |
| Garg et al. | Mucoadhesive drug delivery system in chronic respiratory diseases | |
| Lee et al. | On-demand reconstitutable hyaluronic acid-doped azathioprine microcrystals effectively ameliorate ulcerative colitis via selective accumulation in inflamed tissues | |
| Singh et al. | Harmonious biomaterials for development of in situ approaches for locoregional delivery of anti-cancer drugs: current trends | |
| Sherekar et al. | Fabrication and characterization of nanoencapsulated phyto-compounds | |
| Bajad et al. | Drug Delivery Approaches in the Management of Inflammatory Diseases | |
| TW201946613A (zh) | 用於治療增生性失調的劑量方案 | |
| Stieger et al. | The use of dendrimers to optimize the physicochemical and therapeutic properties of drugs | |
| Chen et al. | Hyaluronic acid microparticles loaded with Shuang-Huang-Lian phospholipid complex for sustained pulmonary delivery: An in vitro and in vivo evaluation | |
| Jani | Pulmonary Applications and Toxicity of Engineered Metallic Nanoparticles |